title: Pharmacologic intervention of skin vasospasm and ischemic necrosis in pigs.
abstract: Ischemic necrosis resulting from vasospasm is a common complication in skin flap surgery, and serotonin released by traumatized platelets is likely to play an important role in the pathogenesis of skin vasospasm in flap surgery. We studied the pathogenic role of serotonin and its pharmacologic intervention thereof in skin flap ischemic necrosis in pigs. We observed that serotonin caused a concentration-dependent (10(-8)-10(-5) M) increase in perfusion pressure in isolated perfused pig skin flaps. This vasoconstrictive effect of serotonin was blocked by S1C/2-serotonergic receptor antagonists LY53857 (10(-5) M) and ketanserin (10(-5) M), but not by an alpha 1-adrenoceptor antagonist (prazosin 10(-5) M), or a thromboxane A2 (TxA2)/endoperoxide receptor antagonist (SQ30741 10(-5) M). The vasoconstrictive effect of serotonin was more pronounced (p < 0.05) in the presence of an endothelium-derived nitric oxide (NO) synthesis inhibitor [N omega-monomethyl-L-arginine (L-NA) or NG-nitro-L-arginine (L-NMMA) 10(-5) M] but not a cyclooxygenase inhibitor (indomethacin 10(-5) M). In in vivo studies, serotonin infusion (5 micrograms/kg/min intravenously, i.v.) significantly (p < 0.05) decreased pig random pattern skin flap capillary blood flow. This in vivo vascular effect was also completely blocked in pigs pretreated with LY53857 (0.4 mg/kg i.v.). In a separate experiment without serotonin infusion, i.v. prazosin (2-8 micrograms/kg), dazmegrel (2-6 mg/kg), or SQ30741 (2-4 mg/kg) had no significant effect on skin flap capillary blood flow as compared with control. On the other hand, i.v. sergolexole or LY53857 significantly (p < 0.05) increased skin flap capillary blood flow in a dose-dependent manner.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Hospital for Sick Children, Department of Physiology, University of Toronto, Ontario, Canada.
authors.forename: C Y
authors.initials: CY
authors.lastname: Pang
authors.forename: C
authors.initials: C
authors.lastname: Chiu
authors.forename: A
authors.initials: A
authors.lastname: Zhong
authors.forename: N
authors.initials: N
authors.lastname: Xu
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000494:pharmacology; D066298:In Vitro Techniques; D007511:Ischemia / Q000503:physiopathology*; D007650:Ketanserin / Q000494:pharmacology; D009336:Necrosis / Q000473:pathology; D044262:Prostaglandin H2; D011463:Prostaglandins H / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D012701:Serotonin / Q000494:pharmacology / Q000502:physiology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D012867:Skin / Q000098:blood supply* / Q000473:pathology; D013524:Surgical Flaps; D013552:Swine; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors; D014661:Vasoconstriction / Q000187:drug effects; D019323:omega-N-Methylarginine
chemical_list: D000317:Adrenergic alpha-Antagonists; D004873:Ergolines; D011463:Prostaglandins H; D012702:Serotonin Antagonists; D019323:omega-N-Methylarginine; D012701:Serotonin; D044262:Prostaglandin H2; D013928:Thromboxane A2; D001120:Arginine; D007650:Ketanserin; C032663:LY 53857